(VIANEWS) - Euroseas Ltd. (ESEA), New York Mortgage Trust (NYMT), Mobile TeleSystems OJSC (MBT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Euroseas Ltd. (ESEA)
166.1% sales growth and 48.23% return on equity
Euroseas Ltd.
Euroseas Ltd.'s sales growth this year is expected to be 75.3% and 59.7% for next year.
Year-on-year quarterly revenue growth grew by 86.9%, now sitting on 67.67M for the twelve trailing months.
Volume
Today's last reported volume for Euroseas Ltd. is 32711 which is 76.99% below its average volume of 142214.
Euroseas Ltd.'s sales growth for the next quarter is 166.1%. The company's growth estimates for the present quarter and the next is 4471.4% and 466%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 48.23%.
Volatility
Euroseas Ltd.'s last day, last week, and last month's current intraday variation average was 1.74%, 1.80%, and 2.56%, respectively.
Euroseas Ltd.'s highest amplitude of average volatility was 9.14% (day), 5.55% (last week), and 6.42% (last month), respectively.
Euroseas Ltd.'s Stock Yearly Top and Bottom Value
Euroseas Ltd.'s stock is valued at $25.21 at 10:22 EST, way under its 52-week high of $39.17 and way above its 52-week low of $5.38.
Euroseas Ltd.'s Moving Average
Euroseas Ltd.'s worth is under its 50-day moving average of $27.04 and way above its 200-day moving average of $22.87.2. New York Mortgage Trust (NYMT)
31.5% sales growth and 10.12% return on equity
New York Mortgage Trust, Inc. acquires, invests in, finances, and manages mortgage-related single-family and multi-family residential assets in the United States.
New York Mortgage Trust's sales growth this year is anticipated to be 11.6% and 48.1% for next year.
Year-on-year quarterly revenue growth declined by 29.1%, now sitting on 320.19M for the twelve trailing months.
Volume
Today's last reported volume for New York Mortgage Trust is 1710190 which is 43.23% below its average volume of 3012710.
New York Mortgage Trust's sales growth for the next quarter is 31.5%. The company's growth estimates for the current quarter and the next is a negative 38.9% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.12%.
Volatility
New York Mortgage Trust's last day, last week, and last month's current intraday variation average was 0.79%, 1.12%, and 1.45%, respectively.
New York Mortgage Trust's highest amplitude of average volatility was 1.59% (day), 2.28% (last week), and 2.73% (last month), respectively.
New York Mortgage Trust's Stock Yearly Top and Bottom Value
New York Mortgage Trust's stock is valued at $3.81 at 10:22 EST, way under its 52-week high of $4.93 and above its 52-week low of $3.51.
New York Mortgage Trust's Moving Average
New York Mortgage Trust's worth is under its 50-day moving average of $3.97 and way under its 200-day moving average of $4.32.3. Mobile TeleSystems OJSC (MBT)
10% sales growth and 381.49% return on equity
Mobile TeleSystems Public Joint Stock Company provides telecommunication services primarily in Russia.
Mobile TeleSystems OJSC's sales growth this year is anticipated to be 7.3% and 4.2% for next year.
Year-on-year quarterly revenue growth grew by 7.1%, now sitting on 524.39B for the twelve trailing months.
Volume
Today's last reported volume for Mobile TeleSystems OJSC is 822216 which is 66.94% below its average volume of 2487290.
Mobile TeleSystems OJSC's sales growth for the next quarter is 10%. The company's growth estimates for the ongoing quarter and the next is 133.3% and 6.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 381.49%.
Volatility
Mobile TeleSystems OJSC's last day, last week, and last month's current intraday variation average was 0.75%, 0.63%, and 1.08%, respectively.
Mobile TeleSystems OJSC's highest amplitude of average volatility was 1.26% (day), 1.26% (last week), and 1.95% (last month), respectively.
Mobile TeleSystems OJSC's Stock Yearly Top and Bottom Value
Mobile TeleSystems OJSC's stock is valued at $7.94 at 10:22 EST, way below its 52-week high of $10.07 and higher than its 52-week low of $7.47.
Mobile TeleSystems OJSC's Moving Average
Mobile TeleSystems OJSC's value is below its 50-day moving average of $8.47 and way under its 200-day moving average of $8.84.4. Royalty Pharma (RPRX)
6.2% sales growth and 15.4% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is anticipated to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.29B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 5830750 which is 170.49% above its average volume of 2155620.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the ongoing quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.4%.
Volatility
Royalty Pharma's last day, last week, and last month's current intraday variation average was 1.86%, 2.98%, and 1.37%, respectively.
Royalty Pharma's highest amplitude of average volatility was 2.20% (day), 3.19% (last week), and 2.37% (last month), respectively.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $42.44 at 10:22 EST, way under its 52-week high of $53.23 and way above its 52-week low of $34.86.
Royalty Pharma's Moving Average
Royalty Pharma's worth is above its 50-day moving average of $38.89 and above its 200-day moving average of $40.64.Previous days news about Royalty Pharma(RPRX)
- According to Bloomberg Quint on Saturday, 8 January, "The company was started by a group of investors led by Pablo Legorreta, the founder and chief executive officer of Royalty Pharma Plc."
- According to Business Insider on Sunday, 9 January, "ProKidney was started by Pablo Legorreta, the founder and CEO of Royalty Pharma (NASDAQ:RPRX). "